[1]杨欢,王华.润肤剂在特应性皮炎基础治疗中应用的研究进展[J].中国皮肤性病学杂志,2014,(01):81-83.
 YANG Huan,WANG Hua.Progress in Clinical Application of Emollient in the Basic Treatment of Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2014,(01):81-83.
点击复制

润肤剂在特应性皮炎基础治疗中应用的研究进展
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2014年01期
页码:
81-83
栏目:
综述
出版日期:
2014-01-20

文章信息/Info

Title:
Progress in Clinical Application of Emollient in the Basic Treatment of Atopic Dermatitis
作者:
杨欢王华
重庆医科大学附属儿童医院,重庆 400014
Author(s):
YANG Huan WANG Hua
(Children's Hospital of Chongqing Medical University)
关键词:
特应性皮炎 保湿 润肤剂 皮肤屏障
Keywords:
Atopic Dermatitis Moisturize Emollient Skin barrier
分类号:
R 758.22
文献标志码:
A
摘要:
特应性皮炎是一种慢性、复发性和炎症性皮肤病,以皮肤干燥、瘙痒和湿疹样外观为主要临床表现。其发病机制复杂,皮肤屏障功能障碍可能是其发生的源头。保湿润肤剂可以补充皮肤水分和脂质,增加水合作用,减少经皮失水率,阻止外界有害物质入侵。润肤剂联合糖皮质激素治疗还可以减少激素用量,减轻其不良反应。传统的润肤剂含有非生理性脂质和表面活化剂,长期应用会破坏皮肤屏障。含有神经酰胺的润肤剂作为本病的基础治疗方案,已被应用于各种年龄段的患者中,且耐受性好,也无严重的不良反应,故具有较高的安全性和有效性。
Abstract:
Atopic dermatitis(AD)is a chronic, recurrent inflammatory disease, with xerosis cutis, pruritus and eczema appearance as the main clinical manifestations.Its pathogenesis was complicated.Dysfunction of skin barrier may be the cause of the disease.Emollient could replenish skin moisture and lipid, increase the hydration, reduce the trans-epidermal water loss and block the invasion of harmful substances.A combination treatment of emollient and glucocorticoid could reduce the dosage of glucocorticoids and reduce its side effects.The traditional emollient contains non-physiologic lipids and surfactants, and long-term use can damage the skin barrier.Ceramide-containing emollient, a basic treatment for AD, has been used in various age groups of patients with good tolerability and without serious untoward reactions, so it has higher safety and effectiveness.

参考文献/References:


[1] Bieber T.Atopic dermatitis[J].Ann Dermatol,2010,22(2):125-137.
[2] Elias PM,Wood LC,Feingold KR.Epidermal pathogenesis of inflammatory dermatoses[J].Am J Contact Dermat,1999,10(3):119-126.
[3] Taïeb A.Hypothesis:from epidermal barrier dysfunction to atopic disorders[J].Contact Dermatitis,1999,41(4):177-180.
[4] Groen D,Poole DS,Gooris GS,et al.Is an orthorhombic lateral packing and a proper lamellar organization important for the skin barrier function?[J] Biochim Biophys Acta,2011,1808(6):1529-1537.
[5] Barnes KC.An update on the genetics of atopic dermatitis:scratching the surface in 2009[J].J Allergy Clin Immunol,2010,125(1):16-29.
[6] Cork MJ,Danby SG,Vasilopoulos Y,et al.Epidermal barrier dysfunction in atopic dermatitis[J].J Invest Dermatol,2009,129(8):1892-1908.
[7] Jakasa I,Koster ES,Calkoen F,et al.Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations[J].J Invest Dermatol,2011,131(2):540-542.
[8] Nemoto-Hasebe I,Akiyama M,Nomura T,et al.Clinical severity correlates with impaired barrier in filaggrin-related eczema[J].J Invest Dermatol,2009,129(3):682-689.
[9] Barker JN,Palmer CN,Zhao Y,et al.Null mutations in the filaggrin gene(FLG)determine major susceptibility to early-onset atopic dermatitis that persists into adulthood[J].J Invest Dermatol,2007,127(3):564-567.
[10] O'Regan GM,Irvine AD.The role of filaggrin in the atopic diathesis[J].Clin Exp Allergy,2010,40(7):965-972.
[11] Jungersted JM,Scheer H,Mempel M,et al.Stratum corneum lipids,skin barrier function and filaggrin mutations in patients with atopic eczema[J].Allergy,2010,65(7):911-918.
[12] 何黎,罗盛军,Kumar Subramanyan.温和保湿洁肤产品对干燥皮肤的临床功效[J].皮肤病与性病,2012,34(3):147-149.
[13] Catherine Mack,Correa M,Nebus J.Management of patients with atopic dermatitis:the role of emollient therapy[J].Dermatol Res Pract,2012; 2012:836931.Epub 2012 Sep 13.
[14] 杨雪源,徐丽敏,周爱民,等.含马齿苋及牛油果树提取物的医学护肤品辅助治疗特应性皮炎的临床观察[J].临床皮肤科杂志,2010(7):460-462.
[15] Simpson EL,Berry TM,Brown PA,et al.A pilot study of emollient therapy for the primary prevention of atopic dermatitis[J].J Am Acad Dermatol,2010,63(4):587-593.
[16] Grimalt R,Mengeaud V,Cambazard F,et al.The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis:a randomized controlled study[J].Dermatology,2007,214(1):61-67.
[17] Msika P,De Belilovsky C,Piccardi N,et al.New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis:SCORAD and quality of life improvement[J].Pediatr Dermatol,2008,25(6):606-612.
[18] Berth-Jones J,Damstra RJ,Golsch S,et al.Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis:randomised,double blind,parallel group study[J].BMJ,2003,326(7403):1367.
[19] 姚燕冰.丁酸氢化可的松乳膏与保湿霜联合治疗幼儿湿疹的疗效观察[J].皮肤病与性病,2011,33(5):285-285.
[20] Kownacki S.The importance of emollients in treating the increasing incidence of atopic eczema[J].Nurs Times,2009,105(28):18-22.
[21] Danby SG,Al-Enezi T,Sultan A,et al.The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis[J].Br J Dermatol,2011,165(2):329-334.
[22] Mohammed D,Matts PJ,Hadgraft J,et al.Influence of Aqueous Cream BP on corneocyte size,maturity,skin protease activity,protein content and transepidermal water loss[J].Br J Dermatol,2011,164(6):1304-1310.
[23] Tsang M,Guy RH.Effect of Aqueous Cream BP on human stratum corneum in vivo[J].Br J Dermatol,2010,163(5):954-958.
[24] Cork MJ,Danby S.Aqueous cream damages the skin barrier[J].Br J Dermatol,2011,164(6):1179-1180.
[25] Frankel A,Sohn A,Patel RV,et al.Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis[J].J Drugs Dermatol,2011,10(6):666-672.
[26] Adkin A,Webster V,Arnold ME,et al.Estimating the impact on the food chain of changing bovine spongiform encephalopathy(BSE)control measures:the BSE control model[J].Prev Vet Med,2010,93(2-3):170-182.
[27] Ganapathi SB,Fox TE,Kester M,et al.Ceramide modulates HERG potassium channel gating by translocation into lipid rafts[J].Am J Physiol Cell Physiol,2010,299(1):74-86.
[28] Uchida Y,Holleran WM,Elias PM.On the effects of topical synthetic pseudoceramides:comparison of possible keratinocyte toxicities provoked by the pseudoceramides,PC104 and BIO391,and natural ceramides[J].J Dermatol Sci,2008,51(1):37-43.

相似文献/References:

[1]于晓虹,宋智琦,刘晓明,等.0.1%他克莫司软膏诱发Kaposi水痘样疹1例[J].中国皮肤性病学杂志,2012,(08):757.
[2]李絮茹,岑醒洪,毕田田,等.维生素D受体激动剂对模型小鼠特应性皮炎的治疗作用[J].中国皮肤性病学杂志,2015,(02):133.[doi:10.13735/j.cjdv.1001-7089.201408080]
 LI Xu ru,CEN Xing hong,BI Tian tian,et al.Effects of Vitamin D Receptor Activators on Atopic Dermatitis Model Mice[J].The Chinese Journal of Dermatovenereology,2015,(01):133.[doi:10.13735/j.cjdv.1001-7089.201408080]
[3]闫毅,蔡莉,陈婷,等.308nm单频准分子光与311nm窄谱中波紫外线照射治疗特应性皮炎的临床疗效比较[J].中国皮肤性病学杂志,2015,(03):251.[doi:10.13735/j.cjdv.1001-7089.201407110]
 YAN Yi,CAI Li,CHEN Ting,et al.Comparison of Efficacy of 308 nm Monochromatic Excimer Light and 311 nm Narrowband Ultraviolet for the Treatment of Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):251.[doi:10.13735/j.cjdv.1001-7089.201407110]
[4]胡海友,王忠永,董大群,等.特应性皮炎的表观遗传研究进展[J].中国皮肤性病学杂志,2015,(04):412.[doi:10.13735/j.cjdv.1001-7089.201404094]
 HU Hai you,WANG Zhong yong,DONG Da qun,et al.Progree of Epigenetic Mechanisms in Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):412.[doi:10.13735/j.cjdv.1001-7089.201404094]
[5]王娟,王芳宇.激肽释放酶与特应性皮炎的关系研究进展[J].中国皮肤性病学杂志,2015,(05):524.[doi:10.13735/j.cjdv.1001-7089.201403041]
 WANG Juan,WANG Fang yu.The Research Progress of Relationships between Kallikreins and Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):524.[doi:10.13735/j.cjdv.1001-7089.201403041]
[6]刘苏俊,徐舰,赵斌,等.非标记定量技术检测特应性皮炎患儿尿液中差异蛋白的应用[J].中国皮肤性病学杂志,2015,(06):640.[doi:10.13735/j.cjdv.1001-7089.201404102]
 LIU Su jun,XU Jian,ZHAO Bin,et al.Application of Labelfree Quantitative Proteomics in Study Differentially Expressed Urinary Proteins in Patients with Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):640.[doi:10.13735/j.cjdv.1001-7089.201404102]
[7]赵巍,刘俊峰,陈达灿,等.半抗原诱导特应性皮炎小鼠模型的研究进展[J].中国皮肤性病学杂志,2015,(08):855.[doi:10.13735/j.cjdv.1001-7089.201407156]
 ZHAO Wei,LIU Jun feng,CHEN Da can,et al.Advances of Hapteninduced Murine Model of Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):855.[doi:10.13735/j.cjdv.1001-7089.201407156]
[8]兰元翎,杨高云.CKLF1及其拮抗肽C19在不同时期特应性皮炎患者外周血T细胞亚群中的作用[J].中国皮肤性病学杂志,2015,(10):1000.[doi:10.13735/j.cjdv.1001.7089.201502096]
 LAN Yuan-ling,YANG Gao yun.Effect of Chemokine like Factor 1 (CKLF1) and CKLF1 Antagonism Peptides C19 on Subsets of Peripheral T Cells of Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):1000.[doi:10.13735/j.cjdv.1001.7089.201502096]
[9]瞿旻晔,袁晓琳,马健.特应性皮炎发病过程及其机制研究现状探讨[J].中国皮肤性病学杂志,2015,(10):1085.[doi:10.13735/j.cjdv.1001.7089.201411037]
 QU Min ye,YUAN Xiao lin,MA Jian.Current Research on Pathogenesis and Mechanism of Atopic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(01):1085.[doi:10.13735/j.cjdv.1001.7089.201411037]
[10]王敏华,艾志琼,黄玲,等.大理市3~19岁儿童及青少年特应性皮炎现况调查[J].中国皮肤性病学杂志,2015,(11):1184.[doi:10.13735/j.cjdv.1001-7089.201412051]
 WANG Min hua,AI Zhi qiong,HUANG Ling,et al.The Prevalence Study of Atopic Dermatitis among Children and Teenagers Aged 3~19 Years in Dali[J].The Chinese Journal of Dermatovenereology,2015,(01):1184.[doi:10.13735/j.cjdv.1001-7089.201412051]

更新日期/Last Update: 2014-01-20